Largest number of cancers was projected to result from abdomen and pelvic CT in adults, reflecting 37 percent of those 103,000 cancers.

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them.